Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Share-based Compensation (2016 - 2025)

Dexcom (DXCM) has disclosed Share-based Compensation for 16 consecutive years, with $35.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 19.17% to $35.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $159.6 million, a 6.34% decrease, with the full-year FY2025 number at $159.6 million, down 6.34% from a year prior.
  • Share-based Compensation was $35.0 million for Q4 2025 at Dexcom, down from $45.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $45.3 million in Q2 2025 to a low of $26.3 million in Q4 2021.
  • A 5-year average of $36.0 million and a median of $35.1 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: dropped 22.87% in 2021, then rose 29.28% in 2022.
  • Dexcom's Share-based Compensation stood at $26.3 million in 2021, then grew by 29.28% to $34.0 million in 2022, then rose by 8.53% to $36.9 million in 2023, then increased by 17.34% to $43.3 million in 2024, then dropped by 19.17% to $35.0 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Share-based Compensation are $35.0 million (Q4 2025), $45.1 million (Q3 2025), and $45.3 million (Q2 2025).